JP2023505273A5 - - Google Patents
Info
- Publication number
- JP2023505273A5 JP2023505273A5 JP2022533626A JP2022533626A JP2023505273A5 JP 2023505273 A5 JP2023505273 A5 JP 2023505273A5 JP 2022533626 A JP2022533626 A JP 2022533626A JP 2022533626 A JP2022533626 A JP 2022533626A JP 2023505273 A5 JP2023505273 A5 JP 2023505273A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitory rna
- pharmaceutical composition
- composition according
- patient
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943943P | 2019-12-05 | 2019-12-05 | |
| US62/943,943 | 2019-12-05 | ||
| PCT/US2020/063475 WO2021113761A1 (en) | 2019-12-05 | 2020-12-04 | Exosomes-based therapy for liver fibrosis and other diseases associated with fibrosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023505273A JP2023505273A (ja) | 2023-02-08 |
| JP2023505273A5 true JP2023505273A5 (https=) | 2023-12-12 |
| JP7674354B2 JP7674354B2 (ja) | 2025-05-09 |
Family
ID=76222148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022533626A Active JP7674354B2 (ja) | 2019-12-05 | 2020-12-04 | 肝線維症および線維症に関連する他の疾患に対するエキソソームベースの療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230013636A1 (https=) |
| EP (1) | EP4069205A4 (https=) |
| JP (1) | JP7674354B2 (https=) |
| KR (1) | KR20220124170A (https=) |
| CN (1) | CN115297850A (https=) |
| AU (1) | AU2020398177A1 (https=) |
| CA (1) | CA3164248A1 (https=) |
| WO (1) | WO2021113761A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3775258A4 (en) | 2018-03-28 | 2022-01-26 | Board of Regents, The University of Texas System | IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES |
| EP3801028A4 (en) | 2018-05-30 | 2022-04-13 | Direct Biologics LLC | A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use |
| US12569517B2 (en) | 2019-02-07 | 2026-03-10 | Direct Biologics, Llc | Method for treating osteoarthritis with mesenchymal stem cell exosomes |
| US12213995B2 (en) | 2019-07-18 | 2025-02-04 | Direct Biologics, Llc | Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use |
| CA3147366A1 (en) * | 2019-08-14 | 2021-02-18 | Adam T. BOUTIN | Extracellular vesicles with stat3-antisense oligonucleotides |
| WO2021158966A1 (en) | 2020-02-05 | 2021-08-12 | Board Of Regents, The University Of Texas System | Diagnostic and prognostic utility of exosomes in immunotherapy |
| CA3171143A1 (en) * | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Targeted delivery of extracellular vesicles |
| KR20230004709A (ko) | 2020-04-22 | 2023-01-06 | 다이렉트 바이오로직스 엘엘씨 | 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물 |
| CN117757792A (zh) * | 2023-12-26 | 2024-03-26 | 圣诺生物医药技术(苏州)有限公司 | 一种用于治疗肝损伤的核酸干扰药物 |
| US12502407B2 (en) | 2024-04-25 | 2025-12-23 | Direct Biologics, Llc | Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7098192B2 (en) * | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
| HRP20160625T1 (hr) * | 2007-09-10 | 2016-08-12 | Boston Biomedical, Inc. | Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka |
| US20100298409A1 (en) * | 2007-09-17 | 2010-11-25 | Intradigm Corporation | Compositions comprising stat3 sirna and methods of use thereof |
| WO2009100446A1 (en) | 2008-02-07 | 2009-08-13 | Terapio, Llc | Compositions for delivery of cargo such as drugs proteins and/or genetic materials |
| US8591905B2 (en) * | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
| EP2411413B1 (en) * | 2009-03-23 | 2016-05-11 | Quark Pharmaceuticals, Inc. | Compounds compositions and methods of treating cancer and fibrotic diseases |
| CN103562215B (zh) * | 2011-04-01 | 2017-04-26 | 埃西斯药品公司 | 信号转导及转录激活蛋白3(stat3)表达的调节 |
| KR20230128139A (ko) * | 2014-10-24 | 2023-09-01 | 아스트라제네카 아베 | 조합물 |
| EP3307890A1 (en) * | 2015-06-10 | 2018-04-18 | Board of Regents, The University of Texas System | Use of exosomes for the treatment of disease |
| US20180200186A1 (en) * | 2015-07-09 | 2018-07-19 | Insmed Incorporated | Compositions and methods for treating lung diseases and lung injury |
| RU2018105118A (ru) * | 2015-08-21 | 2019-09-23 | Пфайзер Инк. | Терапевтические наночастицы, содержащие терапевтический агент, и способы их получения и применения |
| US11512315B2 (en) * | 2018-02-12 | 2022-11-29 | Codiak Biosciences, Inc. | Methods and compositions for macrophage polarization |
| AU2019243179B2 (en) * | 2018-03-28 | 2025-09-18 | Board Of Regents, The University Of Texas System | Use of exosomes for targeted delivery of therapeutic agents |
-
2020
- 2020-12-04 KR KR1020227022785A patent/KR20220124170A/ko active Pending
- 2020-12-04 CN CN202080094331.XA patent/CN115297850A/zh active Pending
- 2020-12-04 CA CA3164248A patent/CA3164248A1/en active Pending
- 2020-12-04 JP JP2022533626A patent/JP7674354B2/ja active Active
- 2020-12-04 WO PCT/US2020/063475 patent/WO2021113761A1/en not_active Ceased
- 2020-12-04 AU AU2020398177A patent/AU2020398177A1/en active Pending
- 2020-12-04 EP EP20897141.6A patent/EP4069205A4/en active Pending
- 2020-12-04 US US17/782,976 patent/US20230013636A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023505273A5 (https=) | ||
| JP7625637B2 (ja) | Ｂ型肝炎ウイルス感染のためのＲＮＡｉ薬 | |
| US12049627B2 (en) | Two-tailed self-delivering siRNA | |
| Klinger et al. | Mesenchymal stem cell extracellular vesicles reverse sugen/hypoxia pulmonary hypertension in rats | |
| JP7488254B2 (ja) | １７β－ＨＳＤ１３型（ＨＳＤ１７Ｂ１３）の発現を阻害するためのＲＮＡｉ剤、その組成物、および使用方法 | |
| JP2026042850A (ja) | アポリポタンパク質Ｃ－ＩＩＩ（ＡＰＯＣ３）の発現を阻害するためのＲＮＡｉ剤および組成物 | |
| CN108779463B (zh) | 使用靶向IL4Rα、TRPA1或F2RL1的RNA复合物治疗特应性皮炎和哮喘 | |
| JP7697889B2 (ja) | アルファ－１アンチトリプシン欠乏症（ａａｔｄ）の治療法 | |
| JP2011516094A5 (https=) | ||
| JP2025061882A (ja) | Ａｐｏｃ３関連疾患および障害の処置のための方法 | |
| KR20250078993A (ko) | 치료용 핵산 및 그의 사용 방법 | |
| JP7846095B2 (ja) | Ｚ－ａａｔタンパク質のレベルを低下させる方法 | |
| JP2023503121A (ja) | Ｃｔｇｆ遺伝子特異的二重鎖オリゴヌクレオチド及びこれを含む線維症関連疾患及び呼吸器関連疾患の予防及び治療用組成物 | |
| JP2012502007A (ja) | 強皮症の治療 | |
| RU2015138544A (ru) | Композиции и способы целенаправленного воздействия на О-связанную N-ацетилглюкозаминтрансферазу и стимулирования заживления ран | |
| WO2022206784A1 (zh) | 一种用于治疗肺纤维化的rna递送系统 | |
| CN115137739A (zh) | 一种用于治疗肺癌的rna递送系统 | |
| CN120040554B (zh) | 环肽类肝靶向化合物、药物组合物及其用途 | |
| CN114127292A (zh) | 减轻反义核酸的毒性的方法 | |
| US20230365969A1 (en) | Methods for inducing adipose tissue remodeling using rnai therapeutics | |
| CN115141848A (zh) | 一种用于治疗亨廷顿病的rna递送系统 | |
| CN115137840A (zh) | 一种用于治疗帕金森的rna递送系统 | |
| EP4437107A1 (en) | Methods for inducing adipose tissue remodeling using rnai therapeutics | |
| WO2025238502A1 (en) | Aluminum adjuvant nanoparticles, methods of manufacture, and uses thereof | |
| WO2025165814A1 (en) | Compositions and methods for regulating cardiac angiogenesis post ischemia |